Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akari CEO Says Synthetic Royalties May Be Used To Fund Coversin Trials

Executive Summary

Akari Therapeutics will explore novel funding options to pay for Phase III trials of Coversin, its lead asset, derived from a native protein discovered in the saliva of the Ornithodoros moubata tick.

Advertisement

Related Content

Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris
Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100284

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel